Stada Recruits Ex-Sandoz Exec To Help Steer Biosimilars
Christine Berndt Previously Headed Biosimilar Development Programs At Sandoz
Stada has announced the appointment of former Sandoz executive Christine Berndt as head of global development for specialty and biosimilar products, replacing Michael Mack.
You may also be interested in...
Executive changes in 2022 reveal how the industry is adjusting to a volatile post-COVID environment.
With generics and biosimilars sales continuing to flow in the first half of 2022, Stada reported healthy top- and bottom-line growth for the first six months of the year, including a 23% rise for its adjusted EBITDA.
The Swedish biotech’s patience paid off as it received a positive EU CHMP opinion on its rare nephrology drug Kinpeygo, known elsewhere as Tarpeyo, following delays related to manufacturing questions.